AMRN Stock Analysis: Buy, Sell, or Hold?
AMRN - Amarin Corp Plc
$14.14
-0.12 (-0.84%)
▼
5d:
+2.39%
30d:
-13.62%
90d:
+0.5%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When AMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AMRN shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
💡 BUY OPPORTUNITY: AMRN shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AMRN is currently trading at $14.14, which is considered slightly low relative to its 30-day fair value range of $13.77 to $15.58. From a valuation perspective, the stock is trading at a discount (Forward PE: -235.7) compared to its historical average (17.3). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, AMRN is showing sideways momentum. The price is approaching resistance at $14.55. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $12.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AMRN is showing sideways momentum. The price is approaching resistance at $14.55. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $12.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$13.77 -
$15.58
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 15.1% above Wall St target ($12.00)
Trading Range Analysis
30-Day Trading Range
$13.77 -
$15.58
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$13.47
Resistance Level
$14.55
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-235.67
Wall Street Target
$12.00
(-15.1%)
Revenue Growth (YoY)
-42.0%
Earnings Growth (YoY)
-94.2%
Profit Margin
-14.6%
PE vs Historical
-235.7 vs 17.3
CHEAP
Share & Embed Analysis
Last updated: August 04, 2026 12:04 AM ET
Data refreshes hourly during market hours. Next update: 1:04 AM
Data refreshes hourly during market hours. Next update: 1:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1277 | 49 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 54 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$357 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$234 | 55 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$270 | 52 HOLD |
